GlassScriptPhysician profile
Joseph Hancox
NPI 1093210288
$3,148.04
in general payments reported to CMS, 2019-2025
25 companies · $951 in 2025
The $951 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $185 · 2023: $889 · 2024: $1,124 · 2025: $951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,865 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,864.54 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $814.07 | 2023-2025 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $335.03 | 2023-2025 | Myfembree |
| Mayne Pharma Commercial LLC | $242.57 | 2023-2025 | |
| Gynesonics, INC. | $176.85 | 2023-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Exeltis, USA INC. | $160.45 | 2022-2025 | Slynd |
| Hologic Sales and Service, LLC | $148.89 | 2023-2025 | Acessa Provu System, Myosure Tissue Removal Device, Fluent Fluid Management System |
| Amgen INC. | $145.78 | 2023-2025 | Evenity, Prolia |
| Abbvie INC. | $130.58 | 2022-2025 | |
| Biogen, INC. | $128.15 | 2024-2025 | Zurzuvae |
| Organon LLC | $102.25 | 2022-2025 | Nexplanon |
| Currax Pharmaceuticals LLC | $91.11 | 2022-2023 | Contrave, Nexlizet, Nexletol |
| Aspira Women'S Health INC | $90.55 | 2022-2024 | Ova1 |
| Optumhealth Care Solutions, LLC | $88.50 | 2023-2025 | Vivify Health Care Team Portal 001, Eitan Medical, Zyno Solutions |
| Millicent US INC | $84.35 | 2024-2025 | Intrarosa, Femlyv |
| Myriad Women'S Health, INC. | $78.80 | 2023 | Myrisk |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $52.98 | 2022-2023 | Injectafer |
| Novo Nordisk INC | $49.32 | 2023-2025 | Wegovy |
| Exact Sciences Corporation | $47.47 | 2025 | Cologuard Collection Kit |
| Channel Medsystems, INC. | $42.19 | 2024 | |
| Coopersurgical, INC. | $35.29 | 2024-2025 | Paragard T 380a, Supercut Hysterectomy Scissors |
| Merck Sharp & Dohme LLC | $28.16 | 2024 | Gardasil 9, Gardasil |
| Myovant Sciences INC. | $28.11 | 2022 | |
| Convatec INC. | $18.00 | 2023 | |
| Medicem INC. | $15.77 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.82 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Hancox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.